drugset / Trial / NCT07038096

ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma

NCT07038096

Phase 1/2 Recruiting 350 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non-randomizedSequentialOpen-labelTreatment

Summary

This study is a randomized, multicenter, Phase Ib/II clinical trial, aimed at evaluating the efficacy and safety of the combination of ZG006 and ZG005 in patients with advanced small cell lung cancer and neuroendocrine carcinoma.

Timeline

Start
2025-09-23
Primary completion
2027-09
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject ZG005 Unknown Intravenous
Subject ZG006 Unknown Intravenous